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The effect of intracoronary and intravenous propranolol on coronary vasomotion was evaluated in 28
patients with coronary artery disease. Luminal area of a normal and a stenotic coronary vessel
segment was determined at rest, during submaximal bicycle exercise and 5min after 1-6 mg sublingual
nitroglycerin administered at the end of the exercise test involving biplane quantitative coronary
arteriography. Patients were divided into three groups: group 1 (n = 12) served as the control group,
group 2 consisted of 10 patients with intracoronary administration of 1 mg propranolol and group 3 of
six patients with intravenous administration of 0-1 mg kg ''propranolol prior to the exercise text.
In the control group there was coronary vasodilation (+23%, P <001) of the normal and coronary
vasoconstriction (—29%, P < 0-001) of the stenotic vessel segment during bicycle exercise. After
sublingual administration of 1-6 mg nitroglycerin there was vasodilation of-both normal (+40%,
P <0-001 vs rest) and stenotic (+12%, NS vs rest) vessel segments. In group 2 intracoronary
propranolol was not accompanied by a change in coronary vessel area but both normal (+13%,
P<0-05) and stenotic (+22%, P<0-05) vessel segments showed coronary vasodilation during
bicycle exercise. After sublingual nitroglycerin there was further vasodilation of both normal (+31 %,
P < 0-001 vs rest) and stenotic (+45%, P < 0-01 vs rest) arteries. In group 3 intravenous
administration of propranolol was associated with a decrease in coronary luminal area of both normal
(—24%, P <0-001) and stenotic (—31%, P <0-001) vessel segments. During dynamic exercise there
was coronary vasodilation of both vessel segments when compared with the data after intravenous
injection of propranolol but there was no change in luminal area (normal vessel —2%, NS vs rest;
stenotic vessel —3%, NS vs rest) when compared with the resting data. After sublingual administration
of 1-6mg nitroglycerin both normal (+21%, P<001) and stenotic (+36%, P<0001) vessel
segments showed coronary vasodilation.
It is concluded that supine bicycle exercise in patients with coronary artery disease is associated with
vasodilation of the normal and vasoconstriction of the stenotic coronary arteries. Intravenous
administration of propranolol is followed by coronary vasoconstriction of both normal and stenotic
coronary arteries, probably due to secondary mechanisms because it is not observed after
intracoronary injection of propranolol and it is overridden by bicycle exercise and sublingual
nitroglycerin.
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intravenous administration of propranolol,
probably due to a decrease in coronary luminal
area. Rafflenbeul and coworkers'3' reported a
decrease in coronary luminal area of the large
and the small epicardial arteries after in-
travenous administration of propranolol. It has
been postulated that beta-adrenergic blockade
potentiates coronary artery vasoconstriction by
the unopposed alpha-adrenergic tone. These
findings contrast with the well-documented
beneficial effect of propranolol in the treatment
of patients with coronary artery disease and
classic angina pectoris in whom adverse
reactions with potentiation of myocardial is-
chaemia are rare. Thus, the purpose of the
present study was to examine the effect of
intracoronary and intravenous propranolol on
coronary vasomotion at rest and during supine
bicycle exercise in patients with coronary artery
disease.
Patients and methods
Twenty-eight patients (mean age 53 years,
range 36 to 67 years) with coronary artery
disease underwent coronary arteriography for
diagnostic purposes (Fig. 1). Previous myocar-
dial infarction was present in 17 patients and a
positive exercise test with ST-segment depres-
sion 3=0-1 mV and/or anginal pain in 26. All
medication was stopped at least 12 to 24 h
before cardiac catheterization. Patients were
selected on a consecutive basis when the
following criteria were fulfilled: a history of
stable angina pectoris with no signs of coronary
vasospasm and a clearly visible coronary artery
stenosis for quantitative evaluation.
QUANTITATIVE CORONARY ARTERIOGRAPHY
After an interval of at least lOmin after the
last diagnostic coronary arteriogram, baseline
biplane coronary arteriography for quantitative
evaluation was carried out after the patient's
feet were attached to the bicycle ergometer'4 5|.
Intracoronary injections of 5 to 7 ml of
amidotrizoate (Urografin 76%) were used for
quantitative coronary arteriography in the first
group of patients, but later during the study 5 to
7 ml of iopamidol (Iopamiro 370) was injected
for quantitative coronary arteriography to
reduce the effect of the contrast medium on
coronary vasodilation. Aortic and pulmonary
Control group
(group 1)
Rest
(n;28)
1mg propranolol i.c
(group 2)
0-1 mg kg"1 propranolol i.v.
(group 3)
16mg nitroglycerin si
(n=28)
Figure 1 Study protocol for the assessment of coronary vasomotion
in 28 patients with coronary artery disease and exercise-induced
angina pectoris using biplane quantitative coronary arteriography.
The control group consisted of 12 patients (group 1) with no
pretreatment prior to the exercise test, group 2 of 10 patients with
intracoronary administration of 1 mg propranolol prior to the
exercise test and group 3 of six patients with intravenous
administration of 0-1 mgkg"1 propranolol prior to the exercise test.
The infusion of propranolol was carried out over 5 min; repeat
coronary arteriography was performed after 6-8 min in group 2 and
after 9-12 min in group 3. At the end of the exercise test 1-6 mg
sublingual nitroglycerin was administered, and S min thereafter
biplane coronary arteriography was repeated, i.c. = intracoronary,
i.v. = intravenous, s.l. = sublingual.
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artery pressure were recorded at rest and at the
end of each exercise level immediately before
coronary arteriography. Repeat coronary angio-
grams were obtained at the end of each exercise
level which was begun at 50 to 75 W and was
increased every 2 min in increments of 25 to
50 W. The exercise test was terminated because
of anginal pain, fatigue or ST-segment depres-
sion of more than 0-2 mV. At the end of the
exercise test 1-6 mg sublingual nitroglycerin was
administered and biplane coronary arteriog-
raphy was repeated 5 min thereafter. There were
no complications related to the procedure in any
of the 28 patients.
Quantitative evaluation of biplane coronary
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Figure 2 Percent changes in normal coronary vessel
segments during exercise in 12 control patients (D), 10
patients with intracoronary administration of 1 mg
propranolol (O) and six patients with intravenous
administration of 0-1 mgkg~' propranolol ( • ) . Data are
given at rest (C), after intracoronary or intravenous
administration of propranolol (PR), during 2 min of
exercise (2 min ex.) and during maximal exercise (max
ex.) as well as 5 min after l-6mg of sublingual
nitroglycerin (NTG).
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Figure 3 Percent changes in coronary stenosis area
during exercise in 12 control patients ( • ) , 10 patients
with intracoronary administration of 1 mg propranolol
(O) and six patients with intravenous administration of
0-1 mgkg"1 propranolol (•) . Data are given at rest (C),
after intracoronary or intravenous administration of
propranolol (PR), during 2 min of exercise (2 min ex.),
during maximal exercise (max ex.) as well as 5 min after
l-6mg sublingual nitroglycerin (NTG).
arteriography was carried out in a blinded
fashion. Tracings were made manually from
both projections during diastasis or end-diastole.
Each vessel segment was analysed four to six
times separately and the results were averaged
to reduce the sampling error'4-51. A section of the
catheter of known dimensions was traced as a
scaling factor. The tracings of the coronary
vessel segments were digitized manually and
analysed on a PDP 11/34 computer1"-51. The
luminal area of a normal and a stenotic vessel
segment was calculated in each patient and
expressed in absolute values and in percent of
the resting value (see Figs 2 and 3).
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STATISTICS
Statistical comparisons of angiographic data in
response to intracoronary or intravenous pro-
pranolol, supine bicycle exercise and sublingual
nitroglycerin were carried out by a two-way
analysis of variance for repeated measurements.
Comparisons between all three groups were
done by a one-way analysis of variance; when
the analysis was significant the Scheffe test was
applied. In both figures mean values ±1
standard error are given.
Results
HAEMODYNAMIC MEASUREMENTS
Administration of intracoronary propranolol
was not associated with a significant change in
heart rate (65 beats min"1 at rest and 64 beats
min"1 after propranolol). However, after in-
travenous administration of propranolol heart
rate decreased significantly (P < 0-05) from 76
beats min"1 at rest to 65 beats min"1 after
propranolol. Mean aortic pressure remained
unchanged after intracoronary or intravenous
administration or propranolol (group 2,
97 mmHg at rest and 98 mmHg after proprano-
lol; group 3, 104 mmHg at rest and 98 mmHg
after propranolol). Heart rate increased sig-
nificantly in all three groups during exercise,
whereas mean aortic pressure showed a
significant increase only in group 1, from
87 mmHg to 107 mmHg ( P < 0-001) but re-
mained unchanged in group 2 (97 vs 93 mmHg,
NS) and group 3 (104 vs 113 mmHg, NS). Mean
pulmonary artery pressure increased significantly
from 26 mmHg to 47 mmHg ( P < 0-001) in
group 1, from 17 mmHg to 41 mmHg (P <
0-001) in group 2 and from 20 mmHg to
36mmHg (P<0001) in group 3.
ANGIOGRAPHIC MEASUREMENTS
Percent changes in coronary luminal area of
the normal vessel segments are shown in Fig. 2
and of the stenotic vessel segments in Fig. 3.
Normal coronary vessel segments showed coro-
nary vasodilation during exercise (±23%,
P < 0 0 1 ) and after sublingual nitroglycerin
(+40%, /><0-001 vs rest) in the control group.
Intracoronary administration of propranolol
(group 2) was not associated with a significant
change in coronary luminal area (+6%, NS) but
during bicycle exercise there was coronary
dilation of the normal vessel segments (+13%,
/ > < 0 0 5 vs rest) which further dilated after
sublingual nitroglycerin (+31%, f><0001 vs
rest). Intravenous administration of propranolol
(group 3) was accompanied with a significant
decrease in coronary luminal area of the normal
vessel segment (-24%, /*<0-001), whereas
bicycle exercise was associated with coronary
vasodilation compared with the angiographic
data after intravenous administration of propra-
nolol, but remained more or less unchanged
compared with the resting data (—2%, NS).
After sublingual nitroglycerin there was coro-
nary vasodilation of normal vessel segments
(+21% P<0-01 vs rest) in group 3.
Stenotic coronary vessel segments (Fig. 3)
showed exercise-induced coronary vasoconstric-
tion in the control group 1 ( -29%, /»< 0-001)
which was prevented after intracoronary ad-
ministration of propranolol (+22%, P < 0 0 5 ) in
group 2. Sublingual nitroglycerin was accom-
panied in both group 1 (+12%, NS vs rest) and
group 2 (+45%, P < 001) by coronary vasodila-
tion. Intravenous administration of propranolol
(group 3) was followed by coronary vasocons-
triction of the stenotic vessel segments ( - 3 1 % ,
P < 0-001). However, during submaximal exer-
cise there was coronary vasodilation of the
stenotic vessel segments compared with the data
after intravenous propranolol, but there was no
change in stenotic vessel segment (—3%, NS vs
rest) compared with the data at rest. Admin-
istration of sublingual nitroglycerin in group 3
was accompanied by a significant increase in
stenotic vessel area (+36%, P < 0-001 vs rest).
Discussion
The reduction in myocardial blood flow after
intravenous administration of propranolol112| has
been attributed to a decrease in coronary
luminal area131, due to the unopposed alpha-
adrenergic vasomotor tone after blockade of the
beta-adrenergic receptors of the epicardial
coronary arteries. Experimental data in the
conscious dog'6' have shown, however, that the
decrease in coronary cross-sectional area after
intravenous administration of propranolol (beta-
1 and beta-2 receptor blockade) or atenolol
(selective beta-1 receptor blockade) is not
prevented by alpha-adrenergic blockade with
either phentolamine or prazosin. It was con-
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eluded that the decrease in coronary cross-
sectional area is probably related to the decrease
in heart rate and contractility, but not due to the
unopposed alpha-adrenergic tone. Since most
patients with classic, exercise-induced angina
pectoris respond well to betablocker treatment,
the reduction in myocardial oxygen consumption
during physical exercise cannot be explained by
the occurrence of coronary vasoconstriction. It is
a well-known fact that epicardial coronary
arteries show vasodilation during dynamic
exercise to meet the increased metabolic
demands of the myocardium'4'5'. If intravenous
administration of propranolol would cause
coronary vasoconstriction during physical exer-
cise, more patients with exercise-induced is-
chaemia would experience an adverse reaction
to betablocker treatment.
The present study shows that intravenous
administration of 0-lmgkg"1 propranolol leads
to a decrease in epicardial luminal vessel area of
both normal and stenotic coronary arteries (Figs
2 and 3) which is not seen after intracoronary
administration of 1 mg propranolol. Heart rate
decreased significantly after intravenous ad-
ministration of propranolol, whereas blood
pressure decreased only slightly but not
significantly. However, after intracoronary in-
jection of propranolol, both heart rate and
blood pressure remained unchanged. These
differences in the haemodynamic determinants
of myocardial oxygen consumption might ex-
plain the decrease in coronary luminal vessel
area after intravenous propranolol, because it
has to be assumed that not only heart rate but
also contractility has decreased, which is another
important determinant of myocardial oxygen
consumption. However, it cannot be ruled out
that the unopposed alpha-adrenergic vasomotor
tone caused coronary vasoconstriction after
intravenous administration of propranolol, as
has been suggested by others'12' but which could
not be confirmed in the conscious dog'6'. The
fact that intracoronary administration of propra-
nolol was not associated with coronary vasocon-
striction supports the previous experimental data
or Vatner and Hintze'61 which showed no direct
effect of the betablockers on coronary vasomo-
tion. It might be, however, that the drug had
been washed out from the coronary vascular tree
before it had blocked the beta-adrenergic
receptors completely.
Dynamic exercise represents a physiological
stimulus for coronary vasodilation to meet the
metabolic demands of the myocardium during
high energy expenditure such as bicycle exercise.
In a previous report'4', we have shown that
normal coronary arteries dilate during dynamic
exercise, but eccentric coronary stenoses show
exercise-induced coronary vasoconstriction. The
exact mechanism of this exercise-induced ste-
nosis narrowing is not clear but might be due to
endothelial dysfunction (atherosclerotic altera-
tions) with an insufficient production of the
endothelium-derived relaxing factor'45' or due to
a passive collapse of the free vessel wall within
the stenosis during high flow states (Venturi
mechanism) such as bicycle exercise'71. Intracor-
onary administration of 1 mg propranolol pre-
vented exercise-induced stenosis narrowing (Fig.
3), and after intracoronary pretreatment with
propranolol there was coronary vasodilation
(+22%, /><005) of the stenotic vessel
segments during dynamic exercise. Intravenous
administration of Olmgkg" 1 propranolol was
associated with a decrease in luminal area of
both normal and stenotic vessel segments (Figs 2
and 3) which was followed by an increase in
coronary vessel area during bicycle exercise. At
the maximal exercise level coronary luminal area
reached its control value of both normal and
stenotic coronary arteries. Sublingual ad-
ministration of 1-6 mg nitroglycerin further
dilated normal and stenotic vessel segments to a
vessel area which was similar (NS) to the control
group. Apparently, intravenous administration
of propranolol is associated with a reduction in
luminal vessel area of the epicardial coronary
arteries, but the response of the coronary
arteries to the dilator stimulus of bicycle exercise
is not affected by the injection of propranolol
prior to the exercise test. This observation
parallels the clinical finding that most patients
with exercise-induced angina pectoris do better
after betablocker treatment because epicardial
coronary arteries are still able to dilate during
exercise, resulting in an increase in coronary
blood flow.
The exact mode of action which prevents
exercise-induced stenosis narrowing after in-
tracoronary and intravenous administration of
propranolol is not clear but might involve the
following mechanisms:
1. The betablocking effect of propranolol
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lessens the autoregulatory rise in coronary blood
flow during exercise and lessens, therefore, the
flow-dependent rise in transstenotic pressure
gradient with a reduced flow-induced fall in
stenosis distending pressure.
2. The rise in coronary vascular resistance after
betablocker administration results in a higher
poststenotic pressure and in a smaller transsten-
otic pressure gradient with a higher stenosis
distending pressure.
3. The local anaesthetic effect of propranolol
leads to a reduced influx of calcium into the
smooth vascular musculature of the epicardial
coronary arteries (calcium-antagonistic action)
which is associated with coronary vasodilation
during bicycle exercise. This mechanism, how-
ever, seems unlikely, since high blood levels of
circulating propranolol are necessary for this
local anaesthetic effect.
The possible role of these three mechanisms
in coronary vasomotion during dynamic exercise
cannot be estimated from our present data.
However, our findings support the good clinical
response to propranolol in most patients with
classic, exercise-induced myocardial ischaemia.
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